<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03415061</url>
  </required_header>
  <id_info>
    <org_study_id>20184334</org_study_id>
    <nct_id>NCT03415061</nct_id>
  </id_info>
  <brief_title>Effect of Intranasal Insulin on POCD and POD</brief_title>
  <official_title>Does Intranasal Insulin Administration Reduce the Incidence of Cognitive Dysfunction After Cardiac Surgery?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hiroaki Sato, MD., PhD.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Decline in cognitive function after surgery occurs most commonly in older patients and&#xD;
      patients undergoing major surgeries, such as heart surgery. Postoperative Cognitive&#xD;
      Dysfunction (POCD) may last a prolonged period of time while Postoperative Delirium (POD) is&#xD;
      a more acute disturbance in attention, awareness and cognition. The cause of POCD and POD are&#xD;
      not fully understood, however some of the pathophysiology of POCD is similar to that of&#xD;
      Alzheimer's disease (AD).&#xD;
&#xD;
      Insulin given intravenously during heart surgery has been shown to preserve short and&#xD;
      long-term memory function after the operation. Clinical trials further demonstrated that&#xD;
      insulin given via the nose (intranasal) improves memory performance of patients with AD or&#xD;
      cognitive impairment suggests that intranasal insulin also could be a therapeutic option for&#xD;
      POCD and POD.&#xD;
&#xD;
      This study is designed to examine the effect intranasal insulin on POCD and POD. The goal is&#xD;
      to investigate whether administration of intranasal insulin during and after heart surgery&#xD;
      improves cognitive function postoperatively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confusion Assessment method for the ICU</measure>
    <time_frame>Up to 7 days after surgery</time_frame>
    <description>Postoperative Delirium is assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rey Auditory Verbal Leaning</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Episodic Memory Lowest score: 0 Highest Score: 15</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rey-Osterrieth Complex Figure Test</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Episodic Memory Lowest score: 0 Highest Score: 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stroop Test</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Executive Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail Making Test</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Executive Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tower of London test</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Executive Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symbol Digit Modalities Test</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Information Processing Speed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Boston Naming Test</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Language Lowest score: 0 Highest score: 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clock Drawing Test</measure>
    <time_frame>up to 12 month</time_frame>
    <description>Visuospatial Function Lowest score: 1 Highest score: 10</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">494</enrollment>
  <condition>Delirium</condition>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>Intranasal Insulin 40 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 IU of Humulin-R via nose Before surgery and everyday after surgery up to postoperative day 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline via nose Before surgery and everyday after surgery up to postoperative day 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular Insulin, Human 100 UNT/ML</intervention_name>
    <description>40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.</description>
    <arm_group_label>Intranasal Insulin 40 IU</arm_group_label>
    <other_name>Humulin R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline Flush, 0.9% Injectable Solution</intervention_name>
    <description>Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery</description>
    <arm_group_label>Intranasal Normal Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢elective open heart surgery requiring cardiopulmonary bypass&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inability to provide informed consent&#xD;
&#xD;
          -  allergy to insulin&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  mother tongue other than English or French&#xD;
&#xD;
          -  visual or hearing impairment interfering with the ability to complete cognitive tests.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Schricker, M.D., PhD.</last_name>
    <phone>5149341934</phone>
    <email>thomas.schricker@mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hiroaki Sato, M.D., PhD.</last_name>
    <phone>5149341934</phone>
    <email>hiroaki.sato2@mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Victoria Hospital McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Hiroaki Sato, M.D.PhD</last_name>
      <phone>5149341934</phone>
      <phone_ext>64275</phone_ext>
      <email>tamaki.sato@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Hiroaki Sato, M.D.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>Chile</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Hiroaki Sato, MD., PhD.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

